Evaluation of Direct-acting Antiviral Drugs for Hepatitis C patients below 30 years age in Sialkot, Pakistan
Kashif Waqasa b, Bushra Noreenc d, Zoya Muzaffare f, Furqan Sabirg h, Syed Zeeshan Haider Naqvib, Javed Anver Qureshia b, Faheem Hadii j, M. Khawar Abbasi j
- aInstitute of Molecular Biology and Biotechnology , The University of Lahore , Pakistan
- bInstitute of Molecular Biology and Biotechnology, The University of Lahore, Pakistan
- cDepartment of Biochemistry , Dera Ghazi Khan Medical College , Dera Ghazi Khan , Pakistan
- dDepartment of Biochemistry, Dera Ghazi Khan Medical College, Dera Ghazi Khan, Pakistan
- eMultan Medical and Dental College , Multan , Pakistan
- fMultan Medical and Dental College, Multan, Pakistan
- gMolecular Department , Pak Medical Centre , Sialkot , Pakistan
- hMolecular Department, Pak Medical Centre, Sialkot, Pakistan
- iUniversity College of Conventional Medicine , Faculty of Medicine and Allied Health Sciences , Islamia University , Bahawalpur , Pakistan
- jUniversity College of Conventional Medicine, Faculty of Medicine and Allied Health Sciences, Islamia University, Bahawalpur, Pakistan
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Background: Infection of Hepatitis C virus (HCV) is major contributor in liver problems, affecting nearly more than 70 million people all over the world. Top ten countries which are affected by Hepatitis, also include Pakistan. Medical science has entered a new era of HCV therapy in elimination of infection and disease is a real possibility. In Asia, Genotype 3 is chronic hepatitis C genotype as compared to other genotypes. Direct-acting antiviral drugs are famous for their high efficacy rate, but less work has done in Asia. Methods: A follow up research was performed to evaluate 3 months treatment outcome of some direct acting antiviral drugs in 35 patients (26 patients of HCV genotype 3) below 30 years of age using some relevant biological parameters. Results: A total of 30 patients yielded a pooled SVR of more than 85% after twelve weeks outcome of commonly used antiviral drugs evaluation. Conclusion: Commonly used antiviral drugs in Sialkot, Pakistan showed effectiveness in HCV patients having genotypes 1, 2, 3 and 5. Keywords: Hepatitis C virus, genotype 3, direct acting antiviral drugs, liver function tests, renal function tests